Scholars@Duke
Joseph Odell Moore

Joseph Odell Moore

Professor Emeritus of Medicine
Medicine, Hematological Malignancies
moore035@mc.duke.edu
Duke Box 3961, Durham, NC 27705
2400 Pratt St., DUMC, Durham, NC 27710

Selected Publications

Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.

Journal Article JAMA Netw Open · June 2, 2025 IMPORTANCE: Therapeutic responses in acute myeloid leukemia (AML) demonstrate considerable variability both across and within established risk stratifications and age groups. Moreover, significant racial disparities persist, with Black patients experiencin ... Full text Link to item Cite

CML and the WHO: Why?

Journal Article J Clin Oncol · March 20, 2024 Full text Link to item Cite

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · February 2024 Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accel ... Full text Link to item Cite

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).

Journal Article Leukemia · January 2024 Clinical outcome of patients with acute myeloid leukemia (AML) is associated with demographic and genetic features. Although the associations of acquired genetic alterations with patients' sex have been recently analyzed, their impact on outcome of female ... Full text Link to item Cite

Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.

Journal Article JAMA Netw Open · December 1, 2023 IMPORTANCE: Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response using tyrosine kinase inhibitors (TKIs) can safely attempt to stop their use. As these medications are very costly, this change in treatment protocols may ... Full text Link to item Cite

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.

Journal Article Blood Adv · October 11, 2022 Survival of patients with acute myeloid leukemia (AML) is inversely associated with age, but the impact of race on outcomes of adolescent and young adult (AYA; range, 18-39 years) patients is unknown. We compared survival of 89 non-Hispanic Black and 566 n ... Full text Open Access Link to item Cite

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Conference Blood · November 5, 2021 AbstractBackground: AML is a highly aggressive hematologic malignancy. Patient (pt) outcomes are affected by disease-related factors including cytogenetic findings and gene mutations, as well as pt-related f ... Full text Cite

Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal Article Cancer Invest · November 2021 Novel therapeutics are needed for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Everolimus is an mTOR pathway inhibitor with synergistic anti-tumor activity when combined with histone deacetylase inhibitors, such as panobi ... Full text Link to item Cite

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.

Journal Article JAMA Oncol · January 1, 2021 IMPORTANCE: Tyrosine kinase inhibitors (TKIs) have been associated with improved survival of patients with chronic myeloid leukemia (CML) but are also associated with adverse effects, especially fatigue and diarrhea. Discontinuation of TKIs is safe and is ... Full text Link to item Cite

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · October 1, 2020 Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chron ... Full text Link to item Cite

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Conference Blood · November 13, 2019 Background: Treatment of chronic myeloid leukemia (CML) with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet has been associated with reduced health-related quality of ... Full text Cite

Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.

Journal Article Br J Haematol · December 2018 Chronic lymphocytic leukaemia (CLL) is characterized by expression of CD5 on clonal B cells, and is partly driven by activated B-cell receptor (BCR) signalling. While CD5 is known to be a negative regulator of BCR signalling, it is unknown if variability i ... Full text Link to item Cite

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Conference Blood · November 29, 2018 AbstractIntroduction:The development of tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis of patients (pts) with chronic myeloid leukemia (CML), with the ... Full text Cite

Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Journal Article Clin Lymphoma Myeloma Leuk · October 2018 BACKGROUND: For patients with aggressive lymphomas who relapse after initial therapy, a durable response is rarely achieved with standard salvage therapies. Significant efforts have focused on the development of novel treatments with reduced toxicity. We c ... Full text Link to item Cite

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · September 2018 Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, ... Full text Link to item Cite

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

Journal Article Blood Adv · July 10, 2018 The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 10 year ... Full text Link to item Cite

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Journal Article BMC Cancer · April 2, 2018 BACKGROUND: Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced health-related quality of life a ... Full text Link to item Cite

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Journal Article J Natl Compr Canc Netw · March 2018 The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN Guidelines Panel meets at least annually to review comments from reviewers within the NCCN Member Ins ... Full text Link to item Cite

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · July 2017 Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides r ... Full text Link to item Cite

Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.

Journal Article J Geriatr Oncol · May 2017 OBJECTIVES: Multiple myeloma (MM) primarily strikes older adults, but full-dose chemotherapy such as bortezomib (Velcade), cyclophosphamide and dexamethasone (VCD) is often excessively toxic to very old or frail adults and those with substantial comorbidit ... Full text Link to item Cite

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · May 2017 This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to asses ... Full text Link to item Cite

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

Journal Article J Natl Compr Canc Netw · December 2016 The NCCN Guidelines for Chronic Myeloid Leukemia (CML) provide recommendations for the management of chronic-phase and advanced-phase CML in adult patients. The median age of disease onset is 67 years. However, because CML occurs in all age groups, clinica ... Full text Link to item Cite

Hodgkin lymphoma, version 2.2015.

Journal Article J Natl Compr Canc Netw · May 2015 Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Weste ... Full text Link to item Cite

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.

Journal Article Leukemia · March 2015 DNMT3B encodes a DNA methyltransferase implicated in aberrant epigenetic changes contributing to leukemogenesis. We tested whether DNMT3B expression, measured by NanoString nCounter assay, associates with outcome, gene and microRNA expression and DNA methy ... Full text Link to item Cite

Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: a comparative study of 67 cases.

Journal Article Am J Clin Pathol · January 2015 OBJECTIVES: To compare the features of the blast phase of chronic myelogenous leukemia (CML) in patients treated with tyrosine kinase inhibitors (TKIs) with those in the pre-TKI era. METHODS: Sixty-seven patients with blast phase CML were identified in the ... Full text Link to item Cite

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Journal Article Proc Natl Acad Sci U S A · December 30, 2014 Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides, located within the intergenic stretches or overlapping antisense transcripts of protein coding genes. LncRNAs are involved in numerous biological roles including imprinting, epigene ... Full text Link to item Cite

Chronic myelogenous leukemia, version 1.2015.

Journal Article J Natl Compr Canc Netw · November 2014 Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable res ... Full text Link to item Cite

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.

Journal Article Leuk Lymphoma · May 2014 Abstract Because of the importance of the phosphoinositide 3-kinase (PI3K)/AKT pathway in chronic lymphocytic leukemia (CLL), we evaluated in vitro cytotoxicity induced by perifosine, an AKT inhibitor, in CLL lymphocytes and found that the mean 50% effecti ... Full text Link to item Cite

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

Journal Article Leuk Lymphoma · December 2013 PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-dai ... Full text Link to item Cite

Chronic Myelogenous Leukemia, Version 1.2014.

Journal Article J Natl Compr Canc Netw · November 2013 The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular ... Full text Link to item Cite

Acute myeloid leukemia, version 2.2013.

Journal Article J Natl Compr Canc Netw · September 1, 2013 These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukem ... Full text Link to item Cite

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Journal Article Blood · May 30, 2013 As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses t ... Full text Link to item Cite

Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.

Journal Article Cancer · March 15, 2013 BACKGROUND: Induction therapy for adults with acute lymphoblastic leukemia (ALL) is similar across essentially all regimens, comprised of vincristine, corticosteroids, and anthracyclines intensified with cyclophosphamide, asparaginase, or both. Given the l ... Full text Link to item Cite

A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.

Journal Article Cancer Invest · March 2013 PURPOSE: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcadeâ„¢) (AAV) for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN: ATO (0.25 mg/kg) and AA (1 g) were ... Full text Link to item Cite

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.

Journal Article Leuk Res · January 2013 PURPOSE: The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The aim of our review was to evaluate the accuracy of a day 14 BM biopsy in dete ... Full text Link to item Cite

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

Journal Article Leukemia · January 2013 Chronic lymphocytic leukemia (CLL) can be immunosuppressive in humans and mice, and CLL cells share multiple phenotypic markers with regulatory B cells that are competent to produce interleukin (IL)-10 (B10 cells). To identify functional links between CLL ... Full text Link to item Cite

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

Journal Article J Clin Oncol · December 20, 2012 PURPOSE: To evaluate the prognostic significance of the international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML). PATIENTS AND METHODS: We analyzed 1,550 adults with primary AML, treated on Cance ... Full text Link to item Cite

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Conference Blood · November 16, 2012 AbstractAbstract 1626Background:Diffuse Large B-cell Lymphoma (DLBCL) patients with primary refractor ... Full text Cite

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Conference Blood · November 16, 2012 AbstractAbstract 4948Background:MDS (Myelodysplastic syndrome) is a hematologic malignancy in which o ... Full text Cite

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Conference Blood · November 16, 2012 AbstractAbstract 4935Background:Myelodysplasticsyndromes (MDS) are a heterogeneous group of hematopoi ... Full text Cite

Implementation of management guidelines for chronic myeloidl leukemia perspectives in the United States

Journal Article P and T · November 1, 2012 Clinical practice guidelines are developed to improve the quality of care and outcomes for patients. Guidelines facilitate clinical decisions, promote efficient use of health care resources, and provide guidance to practitioners. For chronic myeloid leukem ... Cite

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Journal Article J Clin Oncol · September 1, 2012 PURPOSE: To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. PATIENTS AND METHODS: Younger ... Full text Link to item Cite

NCCN Clinical Practice Guidelines Acute myeloid leukemia.

Journal Article J Natl Compr Canc Netw · August 2012 Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML ... Full text Link to item Cite

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

Journal Article Blood · July 12, 2012 High BAALC expression levels are associated with poor outcome in cytogenetically normal acute myeloid leukemia (CN-AML) patients. Recently, miR-3151 was discovered in intron 1 of BAALC. To evaluate the prognostic significance of miR-3151 expression levels ... Full text Link to item Cite

Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML

Journal Article Journal of Geriatric Oncology · July 1, 2012 Objective: Older adults with acute myeloid leukemia (AML) tend to have worse complete remission (CR) rates and overall survival compared to their younger counterparts. At least one reason for this is increased expression of the multidrug resistance gene (M ... Full text Cite

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

Journal Article J Natl Compr Canc Netw · May 2012 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin Lymphoma (HL) include the clinical management of classical HL and lymphocyte-predominant HL (LPHL). Major changes have been incorporated into these guidelines since their incep ... Full text Link to item Cite

Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

Journal Article J Clin Oncol · March 1, 2012 PURPOSE: To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AM ... Full text Link to item Cite

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.

Journal Article Leuk Lymphoma · February 2012 Patients with chronic lymphocytic leukemia (CLL) with deletion or mutation of TP53 have exceedingly poor clinical outcomes. Cenersen, an oligonucleotide targeting TP53, has been shown to abrogate the activity of TP53 gain-of-function mutants and to increas ... Full text Link to item Cite

Chronic myelogenous leukemia.

Journal Article J Natl Compr Canc Netw · January 2012 Full text Link to item Cite

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Journal Article Blood · December 22, 2011 The associations of mutations in the enhancer of trithorax and polycomb family gene ASXL1 with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression profiles in primary cytogenetically normal acute myeloid leukemia (CN-AML) are unkn ... Full text Link to item Cite

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

Journal Article Blood · October 13, 2011 B-cell chronic lymphocytic leukemia (CLL), an incurable leukemia, is characterized by defective apoptosis. We found that the SET oncoprotein, a potent inhibitor of the protein phosphatase 2A (PP2A) tumor suppressor, is overexpressed in primary CLL cells an ... Full text Link to item Cite

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Journal Article Haematologica · October 2011 BACKGROUND: The alleles of the Wilms tumor 1 (WT1) polymorphism rs16754 harbor adenine (A) or guanine (G). Recently, rs16754 has been reported to affect the outcome of patients with cytogenetically normal acute myeloid leukemia. To validate this finding, w ... Full text Link to item Cite

Hodgkin lymphoma.

Journal Article J Natl Compr Canc Netw · September 1, 2011 Full text Link to item Cite

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.

Journal Article Leukemia · May 2011 Untreated de novo (n=421) and secondary (n=189) acute myeloid leukemia (AML) patients ≥60 years received intensified chemotherapy, including daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) during days 1, 2, 3 with cytarabine 100 mg/m(2) during days 1-7, ... Full text Link to item Cite

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Journal Article J Clin Oncol · April 1, 2011 PURPOSE: To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloid leu ... Full text Link to item Cite

Sequential development of histiocytic sarcoma and diffuse large b-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual.

Journal Article Am J Surg Pathol · March 2011 Follicular lymphoma (FL) often transforms to diffuse large B-cell lymphoma (DLBCL) during its protracted clinical course. Rarely, histiocytic sarcoma (HS) occurs secondary to or concurrent with FL, although the biological relationship between these 2 morph ... Full text Link to item Cite

Acute myeloid leukemia.

Journal Article J Natl Compr Canc Netw · March 2011 Full text Link to item Cite

NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

Journal Article J Natl Compr Canc Netw · February 2011 The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). It has become the standard of care for all patients with newly diagnosed chronic-phase CML based on its successful induction of durable responses ... Full text Link to item Cite

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Journal Article Blood · December 16, 2010 BAALC and ERG expression levels are prognostic markers in younger (< 60 years) cytogenetically normal acute myeloid leukemia (CN-AML) adults; their prognostic impact in older (≥ 60 years) patients requires further investigation. We evaluated pretreatment e ... Full text Link to item Cite

A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

Journal Article Clin Lymphoma Myeloma Leuk · December 2010 INTRODUCTION: We evaluated the complete remission (CR) rate in patients with acute myeloid leukemia (AML) in first relapse treated with fixed-dose-rate gemcitabine and mitoxantrone. In addition, we measured multidrug resistance (MDR) proteins on pretreatme ... Full text Link to item Cite

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Journal Article Blood · November 4, 2010 The clinical impact of FLT3-internal tandem duplications (ITDs), an adverse prognostic marker in adults aged < 60 years with primary cytogenetically normal acute myeloid leukemia (CN-AML), requires further investigation in older patients. In CN-AML patient ... Full text Link to item Cite

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

Journal Article J Clin Oncol · September 20, 2010 PURPOSE: Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic malignancies. This study in adults evaluated safety of and compared efficacy of rasburicase alone with rasburicase followed by oral allopurinol and wit ... Full text Link to item Cite

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.

Journal Article Leukemia · September 2010 B-cell chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of malignant cells, which are supported in the microenvironment by cell-cell interactions and soluble cytokines such as tumor necrosis factor (TNF). We evaluated the effect of ... Full text Link to item Cite

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Journal Article Blood · August 5, 2010 We previously reported the adverse prognostic impact of Wilms tumor 1 gene (WT1) mutations in younger adult cytogenetically normal acute myeloid leukemia (CN-AML). Here, we investigated 243 older (> or = 60 years) primary CN-AML patients. WT1 mutated (WT1m ... Full text Link to item Cite

Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.

Journal Article Cancer Invest · July 2010 We present a study of the prevalence of genetic polymorphisms and expression of genes encoding the drug-resistance proteins glutathione S-transferases (GSTs) in order to gain insights into the pattern of failure evident in mantle cell lymphoma. We note a h ... Full text Link to item Cite

Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.

Journal Article Clin Lymphoma Myeloma Leuk · June 2010 PURPOSE: Although alkylators are known to be effective against some myeloid leukemias, resistance is often mediated via O6-alkylguanine-DNA alkyltransferase (AGT). Temozolomide's inhibition of AGT may sensitize leukemia cells to the novel alkylator laromus ... Full text Link to item Cite

Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution.

Journal Article Leuk Lymphoma · May 2010 The biologic relationship between small B-cell lymphoma and histiocytic sarcoma (HS) when occurring in the same patient remains unclear, though recent data suggest a possible 'transdifferentiation' from follicular lymphoma (FL) to HS. We investigated the c ... Full text Link to item Cite

Management of acutemyeloid leukemia in older adults

Chapter · January 1, 2010 Introduction It is estimated that acute myeloid leukemia (AML) accounts for 70 percent of newly diagnosed acute leukemias. In the United States, approximately 13,000 individuals were diagnosed with AML in 2008, and nearly 9,000 died of the disease. Notably ... Full text Cite

Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.

Journal Article Leukemia · January 2010 Monoclonal B-cell lymphocytosis (MBL) is a preclinical hematologic syndrome characterized by small accumulations of CD5(+) B lymphocytes. Most MBL share phenotypic characteristics with chronic lymphocytic leukemia (CLL). Although some MBL progress to CLL, ... Full text Link to item Cite

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Journal Article Biol Blood Marrow Transplant · January 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ... Full text Link to item Cite

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Conference Blood · November 20, 2009 AbstractAbstract 802Background and Significance:Even though we have treatments for CLL, it remains an ... Full text Cite

A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Journal Article Clin Cancer Res · November 15, 2009 PURPOSE: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course. Several parameters have prognostic capabilities but are associated with altered response to therapy in only a small subset of patients. EXPERIME ... Full text Link to item Cite

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

Journal Article J Clin Oncol · November 1, 2009 PURPOSE: A randomized trial of oblimersen plus fludarabine/cyclophosphamide (OBL-FC; n = 120) versus FC (n = 121) was conducted in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The primary end point was met: the complete response (C ... Full text Link to item Cite

Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.

Journal Article Cancer · July 1, 2009 BACKGROUND: Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed. METHODS: The median follow-up of survivors was 2.3 years. A total of 70 (73%) patients achieved a mor ... Full text Link to item Cite

A pilot study on the influence of an individualized and experiential training on cancer caregiver's self-efficacy in home care and symptom management.

Journal Article Home Healthc Nurse · May 2009 The aim of this pilot study was to investigate if an individualized and experiential training can promote family caregiver's confidence (self-efficacy) in home care and symptom management. The study was conducted in a hematology/oncology unit in a southeas ... Full text Link to item Cite

Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.

Journal Article Leukemia · December 2008 Survival of chronic lymphocytic leukemia (CLL) cells requires sustained activation of the antiapoptotic PI-3-K/Akt pathway, and many therapies for CLL cause leukemia cell death by triggering apoptosis. Blood lipoprotein particles are either pro- or antiapo ... Full text Link to item Cite

Acute myeloid leukemia.

Journal Article J Natl Compr Canc Netw · November 2008 Full text Link to item Cite

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Journal Article J Clin Oncol · October 20, 2008 PURPOSE: Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: ... Full text Link to item Cite

Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.

Journal Article Leuk Lymphoma · August 2008 Our aim was to estimate the duration of maximum tolerated dose (MTD) duration for gemcitabine given as a continuous infusion in combination with fludarabine and mitoxantrone and to evaluate potential pharmacokinetic (PK) interactions in 17 patients with re ... Full text Link to item Cite

Intensity of renal support in critically ill patients with acute kidney injury.

Journal Article N Engl J Med · July 3, 2008 BACKGROUND: The optimal intensity of renal-replacement therapy in critically ill patients with acute kidney injury is controversial. METHODS: We randomly assigned critically ill patients with acute kidney injury and failure of at least one nonrenal organ o ... Full text Link to item Cite

CLL cell apoptosis induced by nitric oxide synthase inhibitors: correlation with lipid solubility and NOS1 dissociation constant.

Journal Article Leuk Res · July 2008 Nitric oxide synthase (NOS) inhibitors induce chronic lymphocytic leukemia (CLL) cell apoptosis and have potential as CLL therapeutics. We determined the half-maximal concentration (ED(50)) of 22 NOS inhibitors that induced CLL cell death in vitro. There w ... Full text Link to item Cite

Hodgkin disease/lymphoma.

Journal Article J Natl Compr Canc Netw · July 2008 Full text Link to item Cite

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.

Journal Article Am J Hematol · December 2007 Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgV(H)) mutation status, cytogenetic abnorma ... Full text Link to item Cite

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

Conference Blood · November 16, 2007 AbstractB cell chronic lymphocytic leukemia (CLL), the most common subtype of leukemia in the United States of America and in Europe, is treatable but incurable. New drugs are needed for its management. Phos ... Full text Cite

Monoclonal B Cell Lymphocytosis Exhibits Biologic Diversity Similar to Chronic Lymphocytic Leukemia.

Conference Blood · November 16, 2007 AbstractBackground: Monoclonal B cell lymphocytosis (MBL) is a pre-clinical syndrome characterized by small accumulations of monoclonal B lymphocytes in the peripheral blood. MBL have an immunophenotype simi ... Full text Cite

Monoclonal B Cell Lymphocytosis as a Marker of Inherited Predisposition to Chronic Lymphocytic Leukemia.

Conference Blood · November 16, 2007 AbstractBackground: Segregation analyses suggest that CLL has one of the highest inherited risks among all types of cancer. However, no common germline mutations that confer an inherited predisposition to CL ... Full text Cite

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.

Journal Article Ann Oncol · July 2007 BACKGROUND: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. Modest single-agent clinical activity and tolerability were demonstrated in a phase I study in relapsed o ... Full text Link to item Cite

Chronic myelogenous leukemia.

Journal Article J Natl Compr Canc Netw · May 2007 Full text Link to item Cite

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

Journal Article J Clin Oncol · March 20, 2007 PURPOSE: Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic leukemia (CLL). We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL ... Full text Link to item Cite

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

Journal Article J Clin Oncol · February 20, 2007 PURPOSE: Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related do ... Full text Link to item Cite

Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.

Journal Article Blood · February 15, 2007 Somatic mutations of immunoglobulin genes characterize mature memory B cells, and intraclonal B-cell diversification is typically associated with expansion of B-cell clones with greater affinity for antigen (antigen drive). Evidence for a role of antigen i ... Full text Link to item Cite

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

Journal Article Leuk Res · July 2006 Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO ... Full text Link to item Cite

Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.

Journal Article J Clin Oncol · February 1, 2006 PURPOSE: The treatment of early-stage Hodgkin's disease (HD) has evolved from radiotherapy alone (RT) to combined-modality therapy (CMT) because of concerns about late adverse effects from high-dose subtotal nodal irradiation (STNI). However, there is litt ... Full text Link to item Cite

Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels.

Journal Article Leuk Res · January 2006 B cell chronic lymphocytic leukemia (CLL) CD38 expression is variable and may predict outcome. Inducible nitric oxide synthase (NOS2) expression regulates CLL cell apoptosis. IL-4 and IFN-gamma regulate B cell CD38 expression and NOS2 expression. We compar ... Full text Link to item Cite

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

Journal Article J Clin Oncol · December 20, 2005 PURPOSE: To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML). PATIENTS AND METHODS: Pretreatment blood samples from 84 cytogenetically normal AML patients aged less than 60 ... Full text Link to item Cite

Chronic myelogenous leukemia.

Journal Article J Natl Compr Canc Netw · November 2005 Full text Link to item Cite

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Journal Article J Clin Oncol · August 20, 2005 PURPOSE: Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in acute myeloid leukemia (AML) and confer relatively favorable prognoses, these cytogenetic groups are often treated similarly. Recent studies, however, have shown different gene ... Full text Link to item Cite

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.

Journal Article J Clin Oncol · July 1, 2005 PURPOSE: This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma. PATIENTS AND METHODS: Patients had follicular ly ... Full text Link to item Cite

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

Journal Article J Clin Oncol · June 20, 2005 PURPOSE: Lintuzumab (HuM195) is an unconjugated humanized murine monoclonal antibody directed against the cell surface myelomonocytic differentiation antigen CD33. In this study, the efficacy of lintuzumab in combination with induction chemotherapy was com ... Full text Link to item Cite

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

Journal Article Blood · May 1, 2005 The Cancer and Leukemia Group B (CALGB) study 9222 tested the hypothesis that treatment intensification of acute myeloid leukemia (AML) in first remission with multiple chemotherapy agents is superior to high-dose cytarabine (HiDAC) alone. We enrolled 474 ... Full text Link to item Cite

Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion.

Journal Article Cancer Genet Cytogenet · February 2005 We performed chromosome analysis on the bone marrow of a patient with BCR/ABL negative chronic myelogenous leukemia (CML). By interphase fluorescence in situ hybridization (FISH), an extra ABL signal was present in interphase nuclei and appeared to be loca ... Full text Link to item Cite

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

Journal Article J Clin Oncol · January 20, 2005 PURPOSE: Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML). PATIENTS AND METHODS: In 490 patients, induction included cytarabine and daunorubicin (AD) or cytara ... Full text Link to item Cite

Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer

Journal Article Journal of Applied Research · December 1, 2004 Purpose: To report our clinical experience with 25 patients receiving concurrent capecitabine and irradiation in the treatment of locally advanced or resected pancreatic cancer. Methods and Materials: We reviewed the medical records of patients with pancre ... Cite

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

Journal Article J Clin Oncol · November 1, 2004 PURPOSE: P-glycoprotein (Pgp) is strongly inhibited by PSC-833. A chemotherapy dose-escalation study was performed with PSC-833 in patients younger than 60 years with untreated acute myeloid leukemia. Clinical rather than pharmacokinetic end points were us ... Full text Link to item Cite

Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.

Journal Article Cancer · November 1, 2004 BACKGROUND: Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic ut ... Full text Link to item Cite

Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.

Journal Article Clin Lymphoma · September 2004 A retrospective review was performed on the toxicity and response to one cycle of dose-intense cyclophosphamide/etoposide, followed by consolidation in patients with refractory or previously untreated, high-risk non-Hodgkin's lymphoma (NHL). Fifty-five pat ... Full text Link to item Cite

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.

Journal Article Blood · August 1, 2004 We report a phase 1 study of pharmacokinetics, dosimetry, toxicity, and response of (131)I anti-tenascin chimeric 81C6 for the treatment of lymphoma. Nine patients received a dosimetric dose of 370 MBq (10 mCi). Three patients received an administered acti ... Full text Link to item Cite

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.

Journal Article Cancer · June 1, 2004 BACKGROUND: Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high-dose taxanes have not bee ... Full text Link to item Cite

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.

Journal Article Blood · June 1, 2004 Whites have a more favorable prognosis than African Americans for a number of cancers. The relationship between race and outcome is less clear in acute myeloid leukemia (AML). Using data from 7 Cancer and Leukemia Group B studies initiated from 1985 to 199 ... Full text Link to item Cite

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

Journal Article J Clin Oncol · March 15, 2004 PURPOSE: To study the impact of repetitive (three to four courses) versus a single course of high-dose cytarabine (HDAC) consolidation therapy on outcome of patients with acute myeloid leukemia (AML) and inv(16)(p13q22) or t(16;16)(p13;q22). PATIENTS AND M ... Full text Link to item Cite

Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.

Journal Article Ann Hematol · 2004 The current cure rate of 80% in childhood acute lymphoblastic leukemia (ALL) attests to the effectiveness of risk-directed therapy developed through well-designed clinical trials. The ongoing Total Therapy Study XV at St. Jude Children's Research Hospital ... Full text Link to item Cite

The impact of minimally invasive parathyroidectomy on the way endocrinologists treat primary hyperparathyroidism.

Conference Surgery · December 2003 BACKGROUND: Minimally-invasive parathyroidectomy (MIP) appears to be changing preoperative treatment and referral patterns for sporadic, nonfamilial, non-multiple endocrine neoplasia, primary hyperparathyroidism (PHPT). METHODS: The American Association of ... Full text Link to item Cite

Rituximab in lymphocyte predominance Hodgkin's disease: a case series.

Journal Article Clin Lymphoma · September 2003 Rituximab in combination with chlorambucil or radiation therapy may be an effective and less-toxic therapeutic alternative for patients with lymphocyte predominance Hodgkin's disease (LPHD). We treated 6 patients with LPHD with weekly rituximab at 375 mg/m ... Full text Link to item Cite

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Journal Article Blood · September 1, 2003 Cytogenetic aberrations are important prognostic factors in acute myeloid leukemia (AML). Of adults with de novo AML, 45% lack cytogenetic abnormalities, and identification of predictive molecular markers might improve therapy. We studied the prognostic im ... Full text Link to item Cite

Cytogenetic and molecular analysis of an unusual case of acute promyelocytic leukemia with a t(15;17;17)(q22;q23;q21).

Journal Article Cancer Genet Cytogenet · August 2003 We present a 52-year-old female with a clinical history of acute myelocytic leukemia, probable acute promyelocytic leukemia (APL). Flow cytometry results were somewhat unusual. Specifically, the promyelocytic population showed partial positivity for antige ... Full text Link to item Cite

Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases.

Journal Article Am J Surg Pathol · June 2003 We report five cases of Burkitt lymphoma arising in organ transplant recipients. There were four men and one woman with a mean age of 35 years. All were solid organ recipients with three renal, one liver, and one double lung transplantation. The time inter ... Full text Link to item Cite

Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.

Journal Article Clin Cancer Res · February 2003 PURPOSE: The purpose of this study was to determine the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with fludarabine at 25 mg/m(2) daily for 5 days in the treatment of relapsed or refractory acute myelogenous leuk ... Link to item Cite

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

Journal Article J Clin Oncol · February 1, 2003 PURPOSE: The primary objective was to assess the duration of grade 4 neutropenia (neutrophil count < 0.5 x 10(9)/L) after one cycle of chemotherapy with etoposide, methylprednisolone, cisplatin, and cytarabine in patients randomly assigned to receive one d ... Full text Link to item Cite

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Journal Article Blood · December 15, 2002 We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-year overall survival (OS). ... Full text Link to item Cite

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Journal Article Int J Oncol · November 2002 Isolated trisomy is a relatively common cytogenetic abnormality in acute myeloid leukemia (AML), but with uncertain prognostic significance. We studied a large cohort of newly diagnosed de novo AML patients karyotyped on CALGB 8461 from 1984-1999, where tr ... Link to item Cite

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

Journal Article J Clin Oncol · July 1, 2002 PURPOSE: To estimate the maximum-tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with irinotecan at 40 mg/m(2) daily for 3 days in the treatment of relapsed or refractory acute leukemia or lymphoma. PATIENTS AND METHODS: Pati ... Full text Link to item Cite

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

Journal Article Leuk Lymphoma · May 2002 Twenty-three adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) were treated for up to 12 weeks with the anti-CD52 monoclonal antibody alemtuzumab. Patients were a median of six years from diagnos ... Full text Link to item Cite

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.

Journal Article J Clin Oncol · February 1, 2002 PURPOSE: To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia. PATIENTS AND METHODS: Thirty-four patients were enrolled. ... Full text Link to item Cite

Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.

Journal Article Leukemia · December 2001 Fludarabine is active but not curative in the treatment of chronic lymphocytic leukemia (B-CLL). Nitric oxide (NO) supplied from exogenous, NO-donating pro-drugs can also induce apoptosis and death of acute leukemia cells. This study investigated combinati ... Full text Link to item Cite

Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.

Journal Article J Surg Oncol · November 2001 BACKGROUND AND OBJECTIVES: Osteosarcoma is a primary malignancy of bone. Current therapy includes neoadjuvant chemotherapy, surgery, and postoperative (adjuvant) chemotherapy. Prolonged treatment with chemotherapeutic agents may place patients at increased ... Full text Link to item Cite

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

Journal Article Blood · August 1, 2001 The treatment of older patients with acute myeloid leukemia (AML) remains unsatisfactory, with complete remission (CR) achieved in only approximately 50% and long-term disease-free survival in 10% to 20%. Three hundred eighty-eight patients (60 years of ag ... Full text Link to item Cite

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

Journal Article Blood · June 1, 2001 Multiparameter flow cytometry (MFC) has the potential to allow for sensitive and specific monitoring of residual disease (RD) in acute myeloid leukemia (AML). The use of MFC for RD monitoring assumes that AML cells identified by their immunophenotype at di ... Full text Link to item Cite

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

Journal Article J Clin Oncol · March 15, 2001 PURPOSE: To determine the maximum-tolerated dose, pharmacokinetic interaction, and activity of PSC 833 compared with daunorubicin (DNR) and cytarabine in patients with poor-risk acute myeloid leukemia. PATIENTS AND METHODS: Patients received ara-C 3 g/m(2) ... Full text Link to item Cite

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

Journal Article J Clin Oncol · December 1999 PURPOSE: To examine the effect of single compared with repetitive (at least three) cycles of high-dose cytarabine after induction therapy for patients with acute myeloid leukemia (AML) who have the t(8;21)(q22;q22) karyotype. PATIENTS AND METHODS: Patients ... Full text Link to item Cite

Post transplant CD8+ gammadelta T-cell lymphoma associated with human herpes virus-6 infection.

Journal Article Leuk Lymphoma · April 1999 Gammadelta T-cell lymphoma is a rare T-cell lymphoproliferative disorder that has been reported in both immunocompetent and immunocompromised persons. This report describes a forty eight year old patient who developed gammadelta T-cell lymphoma four years ... Full text Link to item Cite

Follicular mucinosis as a presenting sign of acute myeloblastic leukemia.

Journal Article J Am Acad Dermatol · May 1998 Follicular mucinosis is often associated with mycosis fungoides and has been rarely observed to occur with other neoplastic and inflammatory conditions. We describe a 60-year-old patient with follicular mucinosis who later developed acute myelogenous leuke ... Full text Link to item Cite

Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

Journal Article Blood · December 1, 1997 Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9; 11)(p22; q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult d ... Link to item Cite

Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.

Journal Article Am J Clin Pathol · June 1997 The CD56 antigen is normally expressed on natural-killer cells but has additionally been shown to be present on a variety of hematologic malignancies, including a subset of acute myelogenous leukemia (AML). There is disagreement, however, about its prognos ... Full text Link to item Cite

Craniocerebral plasmacytoma: MR features.

Journal Article AJNR Am J Neuroradiol · February 1997 We report the MR imaging findings in two patients with solitary craniocerebral plasmacytoma, a benign plasma cell tumor that can arise from the skull, the dura, or, rarely, the brain. In both patients, the lesion was extraaxial and nearly isointense with g ... Link to item Cite

Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

Journal Article J Clin Oncol · February 1997 PURPOSE: To examine the prognostic significance of extramedullary leukemia (EML) at presentation in patients with t(8;21)(q22;q22) karyotype. PATIENTS AND METHODS: Consecutive patients with t(8;21) treated on Cancer and Leukemia Group B de novo acute myelo ... Full text Link to item Cite

Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.

Journal Article Blood · February 1, 1997 This study evaluated the effect of filgrastim (granulocyte colony-stimulating factor [G-CSF]) on the duration of granulocytopenia and thrombocytopenia after intensive consolidation therapy with diaziquone (AZO) and mitroxantrone for patients less than 60 y ... Link to item Cite

Arthritis syndromes associated with human T cell lymphotropic virus type I infection.

Journal Article Med Clin North Am · January 1997 Arthritis syndromes occur associated with HTLV-I infection both in the presence and in the absence of clinical ATL, and polyarthritis may be the presenting manifestation of HTLV-I-associated ATL. In both clinical settings, HTLV-I-infected T cells home to a ... Full text Link to item Cite

A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.

Journal Article Blood · May 1, 1996 Thrombocytopenia is a complication of cancer treatment that can limit dose intensity. Interleukin-11 (IL-11) is a growth factor that increases platelet production. We conducted a multicenter, randomized, placebo-controlled trial of recombinant human IL-11 ... Link to item Cite

Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).

Journal Article Leukemia · September 1995 A phase III clinical trial was designed to determine if more intensive induction and consolidation therapy for acute myeloblastic leukemia increases the remission rate and prolongs survival. A minor objective was to determine if the use of non-cross resist ... Link to item Cite

Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells.

Journal Article Leuk Res · August 1995 Freshly isolated acute non-lymphocytic leukemia (ANLL) cells were treated with the nitric oxide (NO)-liberating compounds sodium nitroprusside or S-nitrosoacetyl penicillamine and analyzed for viability, growth, and differentiation at 3-5 days. NO decrease ... Full text Link to item Cite

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

Journal Article N Engl J Med · June 22, 1995 BACKGROUND: Elderly patients with primary acute myelogenous leukemia (AML) are less likely to enter remission than younger adults, in part because of a higher mortality rate related to severe myelosuppression. Granulocyte-macrophage colony-stimulating fact ... Full text Link to item Cite

Predictors of outcome of tricuspid valve replacement in carcinoid heart disease.

Journal Article Am J Cardiol · March 1, 1995 The cardiac valvular surgical experience of patients in the Duke Carcinoid Database was reviewed to assess operative outcome. Of the 604 patients in the database, 19 patients with carcinoid heart disease were identified by cardiac catheterization or echoca ... Full text Link to item Cite

A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.

Journal Article Leukemia · November 1994 A phase III clinical trial was developed to test whether the addition of etoposide to a high-dose cytosine arabinoside regimen would improve the remission rate, duration of remission, and survival in relapsed and refractory patients with acute myelogenous ... Link to item Cite

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Journal Article N Engl J Med · October 6, 1994 BACKGROUND: About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, such responses are rarely durable when conventional postremission the ... Full text Link to item Cite

A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease.

Journal Article Cancer · July 1, 1994 BACKGROUND: Advanced stage Hodgkin's disease (HD) usually is treated with combination chemotherapy with or without supplemental irradiation. The risk of significant acute and long term toxicity when the chemotherapy regimen contains alkylating agents has p ... Full text Link to item Cite

Hepatosplenic T-cell lymphoma: an unusual case of a gamma delta T-cell lymphoma with a blast-like terminal transformation.

Journal Article Hum Pathol · January 1994 We describe a case of a middle-aged women who presented with anemia and mild hepatosplenomegaly and who was found to have an unusual peripheral T-cell lymphoma with only subtle morphologically abnormal but mature-appearing cells noted in the blood and bone ... Full text Link to item Cite

Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow.

Journal Article J Natl Cancer Inst · December 15, 1993 BACKGROUND: Cigarette smoking may be a risk factor for leukemia. No detailed biological mechanism has been proposed, but a causal link is made plausible by evidence of systemic effects of cigarette smoke and the presence in cigarette smoke of chemicals tha ... Full text Link to item Cite

The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.

Journal Article Cancer · January 15, 1993 BACKGROUND: A case of reversible cardiogenic shock linked to 5-fluorouracil (5-FU) was observed. Recognizing the increasing use of 5-FU, the authors tried to map this syndrome. METHODS: They reviewed 134 additional case reports, retrieved information from ... Full text Link to item Cite

CALGB studies with hematopoietic growth factors in patients with AML

Journal Article Leukemia and Lymphoma · January 1, 1992 Full text Cite

The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.

Journal Article Br J Haematol · September 1991 The sensitivity to lysis by complement of the erythrocytes of 56 patients with paroxysmal nocturnal haemoglobinuria (PNH) was compared to the membrane expression of decay accelerating factor (DAF, CD55), membrane inhibitor of reactive lysis (MIRL, CD59) an ... Full text Link to item Cite

Improved survival in advanced Hodgkin's disease with the use of combined modality therapy.

Journal Article Int J Radiat Oncol Biol Phys · September 1990 To compare the effectiveness of combined modality therapy and chemotherapy alone for the treatment of advanced Hodgkin's disease (Stages IIB-IV), records of 154 patients who achieved a complete or partial response to induction combination chemotherapy were ... Full text Link to item Cite

The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.

Journal Article Cancer · August 1, 1990 Forty-five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5-fluorouracil, and methotrexate with folinic acid rescue. This regimen was designe ... Full text Link to item Cite

Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine.

Journal Article J Neurosurg · April 1990 Seventeen patients with recurrent gliomas were treated with the combination of cyclophosphamide and vincristine. All but one had previously received and failed chemotherapy. Cyclophosphamide was administered at doses ranging from 250 to 1000 mg/sq m by int ... Full text Link to item Cite

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.

Journal Article Leukemia · March 1990 This phase III, randomized trial in previously untreated adults with ANLL compared mitoxantrone plus cytosine arabinoside with the CALGB "7 + 3" daunorubicin-based regimen. Two hundred evaluable patients (98 treated with the mitoxantrone-based regimen and ... Link to item Cite

Surgical management of pancreatic lymphoma.

Journal Article Arch Surg · November 1989 The clinical and pathologic records of 12 patients with pancreatic lymphoma were reviewed retrospectively to determine distinguishing clinical features. Radiologically, all patients had large abdominal masses in the region of the pancreas. Preoperative per ... Full text Link to item Cite

Hodgkin's disease presenting as myelofibrosis.

Journal Article Cancer · October 15, 1989 Four patients with Hodgkin's disease and bone marrow fibrosis are presented in whom the clinical presentation was dominated by cytopenias; this was associated with a delayed diagnosis for an average of 20 months. Despite marrow involvement, chemotherapy re ... Full text Link to item Cite

Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin.

Journal Article Blood · October 1989 Previously we showed that starvation of HL-60 promyelocytic leukemia cells for a single essential amino acid induced irreversible differentiation into more mature monocyte-like cells. Although not an essential amino acid, glutamine is important in the grow ... Link to item Cite

Carcinoid tumors: iodine-131 MIBG scintigraphy.

Journal Article Radiology · September 1989 Eighty-two patients with pathologically proved carcinoid tumors were examined with iodine-131 metaio-dobenzylguanidine (MIBG) scintigraphy. Localization scores of I-131 MIBG accumulation in the primary tumor or metastatic site ranged from 0 to 3+ on the ba ... Full text Link to item Cite

Familial aggregation of multiple myeloma and central nervous system diseases.

Journal Article J Am Geriatr Soc · April 1989 Degenerative central nervous system diseases such as Alzheimer's disease and lymphoreticular malignancies such as multiple myeloma occur with increased frequency with advancing age. Relatives of early-onset Alzheimer's disease patients may have an increase ... Full text Link to item Cite

Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia.

Journal Article Am J Clin Pathol · March 1989 The authors performed membrane antigen phenotyping on 75 patients with acute nonlymphocytic leukemia with a panel of myeloid-associated monoclonal antibodies. The 34 patients (45%) with CD34-positive leukemia were not significantly different from the 41 wi ... Full text Link to item Cite

CD7+, CD4-, CD8- acute leukemia: a syndrome of malignant pluripotent lymphohematopoietic cells.

Journal Article Blood · February 1989 Following our initial observation of in vivo conversion of CD7+, CD4-, CD8- acute lymphoblastic leukemia (ALL) cells from lymphoid to myeloid lineages (Proc Natl Acad Sci (USA) 81:253, 1984) we have studied eight additional cases of ALL with this leukemic ... Link to item Cite

Biogenic amines in carcinoid tumors

Journal Article Biogenic Amines · January 1, 1989 We determined the content of serotonin (5-HT), dopamine (DA), norepinephrine (NE) and epinephrine (E) in the tumors and urine of 12 patients with carcinoid tumors of midgut origin and 14 patients with carcinoid tumors of foregut origin. All of the midgut c ... Cite

A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy.

Journal Article Int J Hyperthermia · 1989 Research in animal and human cell cultures has shown that some chemotherapeutic agents, cisplatin in particular, have cytotoxicity that is significantly potentiated at elevated temperatures. Concurrent administration of systemic cisplatin and local hyperth ... Full text Link to item Cite

High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

Journal Article Cancer Chemother Pharmacol · 1989 A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 18 ... Full text Link to item Cite

Demonstration of phenotypic abnormalities of thymic epithelium in thymoma including two cases with abundant Langerhans cells.

Journal Article Am J Pathol · September 1988 A panel of monoclonal antibodies that phenotypically define stages of normal human thymic epithelial (TE) cell maturation was used to compare thymic epithelium of nine thymomas with hyperplastic thymic epithelium in myasthenia gravis (MG) and thymic epithe ... Link to item Cite

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

Journal Article J Clin Oncol · September 1988 To evaluate the effect of high-dose chemotherapy in the treatment of metastatic breast cancer, we performed a phase II trial of a single treatment with high-dose cyclophosphamide (5,625 mg/m2), cisplatin (165 mg/m2), and carmustine (600 mg/m2), or melphala ... Full text Link to item Cite

Pleural amyloidosis.

Journal Article Arch Pathol Lab Med · January 1988 Pleural amyloidosis has been reported rarely, and the diagnosis of this disease by Cope needle biopsy has, to our knowledge, been reported only once previously. We report two patients in whom the diagnosis of pleural amyloidosis was made by biopsy specimen ... Link to item Cite

Computed tomography of primary retroperitoneal malignancies.

Journal Article J Comput Assist Tomogr · 1988 The CT examinations and medical records of 33 patients with primary retroperitoneal malignancies were reviewed. Computed tomography findings were then compared with those from scans performed on 122 patients with non-Hodgkin lymphoma who presented during t ... Full text Link to item Cite

Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors.

Journal Article Cancer Res · December 1, 1987 A Phase I-II clinical trial of high dose single agent busulfan (16-20 mg/kg) administered over a 4-day period was undertaken. Pharmacokinetic measurements reveal that steady state total plasma busulfan levels between 2 and 10 microM were achieved by the se ... Link to item Cite

Sarcomas in the elderly.

Journal Article Clin Geriatr Med · November 1987 Though rare, osteosarcomas and soft tissue sarcomas do occur in the geriatric population. When possible, surgical excision is the treatment of choice, with radiation therapy and chemotherapy having largely an adjuvant role. Classic Kaposi's sarcoma is a ch ... Link to item Cite

Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults.

Journal Article Am J Med · October 23, 1987 The standard schedule for treating immune thrombocytopenia purpura in adults with intravenous immunoglobulin G infusion (IVIG), 400 mg/kg per day for five days, was compared with a shorter schedule using 1,000 mg/kg per day for two days. Both schedules wer ... Full text Link to item Cite

Prevention of amphotericin B-induced rigors by dantrolene.

Journal Article Arch Intern Med · August 1986 Three patients had severe amphotericin B-induced rigors refractory to conventional prophylactic measures. Rigors improved or disappeared when dantrolene sodium was given prophylactically or during an episode. These observations suggest that dantrolene is u ... Link to item Cite

Intraluminal thrombus and bowel obstruction in acute leukemia due to bleeding Meckel's diverticulum.

Journal Article Am J Med · June 1986 Gastrointestinal bleeding from Meckel's diverticulum resulted in small bowel obstruction by thrombus in two patients with acute myelogenous leukemia during bone marrow aplasia and recovery from induction chemotherapy. Although gastrointestinal symptoms and ... Full text Link to item Cite

Primary intraaortic malignancy--a case report.

Journal Article Cardiovasc Intervent Radiol · 1986 Malignant peripheral arterial emboli are extremely unusual. Most reported cases of malignant arterial emboli are secondary to invasion of the systemic circulation by pulmonary malignancies via the pulmonary veins. We report a rare case of a primary sarcoma ... Full text Link to item Cite

Phase I-II trial of mitoxantrone in acute leukemia: an interim report.

Journal Article Invest New Drugs · 1985 We evaluated the effect of mitoxantrone (Novantrone; dihydroxyanthracenedione) in the treatment of refractory acute leukemia and acute leukemia in relapse. In this study, 70 patients are currently evaluable. Of the 25 patients who received mitoxantrone 10 ... Full text Link to item Cite

Specific receptors for phorbol diesters on freshly isolated human myeloid and lymphoid leukemia cells: comparable binding characteristics despite different cellular responses.

Journal Article Blood · February 1984 Freshly isolated human leukemia cells have been shown in the past to display varying in vitro responses to phorbol diesters, depending on their cell type. Specific receptors for the phorbol diesters have been demonstrated on numerous different cells. This ... Link to item Cite

Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.

Journal Article Proc Natl Acad Sci U S A · January 1984 Selective failure of lymphoid development occurs in genetic deficiency of adenosine deaminase (ADA). We examined the in vivo effects of a potent inhibitor of ADA, 2'-deoxycoformycin, which was used to treat a patient with refractory acute leukemia. Unexpec ... Full text Link to item Cite

Mitoxantrone in the treatment of relapsed and refractory acute leukemia

Journal Article Seminars in Oncology · January 1, 1984 Eleven academic institutions were selected to study mitoxantrone administered on a schedule of 10 mg/ m2/d for five days initially and later at 12 mg/m2/d for five days, each given as a 30 minute intravenous (IV) infusion each day. Pa ... Cite

Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma.

Journal Article Cancer Treat Rep · November 1983 Nineteen patients with advanced metastatic colon carcinoma were treated with human lymphoblastoid interferon at a dose of 3.0 X 10(6) units/m2 im three times/week for 6 weeks. Patients who did not progress at the 6-week interval were randomized to receive ... Link to item Cite

Septic arthritis due to Mycoplasma hominis.

Journal Article Arthritis Rheum · August 1983 Full text Link to item Cite

Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis.

Journal Article Proc Natl Acad Sci U S A · April 1983 We have identified a Japanese patient with adult T-cell leukemia (ATL) whose T cells in vitro produced the human T-cell leukemia virus (HTLV). This patient presented with lymphomatous arthritis and leukemia and subsequently developed skin lesions. Skin inv ... Full text Link to item Cite

Medusa cells: cytostructure and cytochemistry of amoeboid eosinophils with pseudopod-like processes.

Journal Article Histochem J · November 1981 Eosinophils having one or more pseudopod-like processes of various lengths are observed in bone marrow, peripheral blood, sputum, nasal smears, and in other exfoliative cytology and tissue specimens after fixation and staining for histochemical study; they ... Full text Link to item Cite

Mental neuropathy from systemic cancer.

Journal Article Neurology · October 1981 Nineteen patients with mental neuropathy secondary to systemic cancer are described. In nine patients, the numb chin was the presenting symptom of a neoplasm. Nine patients had lymphoreticular malignancies, and the others had a variety of solid tumors. Rad ... Full text Link to item Cite

Detection and partial characterization of human thymus-leukemia antigens.

Journal Article J Natl Cancer Inst · October 1980 Two monkey antisera against human thymocytes after absorption with human erythrocytes and peripheral blood leukocytes were shown to detect human thymus-leukemia (HTL)-like antigens. These sera were cytotoxic for thymocytes (> 90% lysis at a 1:10 dilution) ... Full text Link to item Cite

Malignant effusions in recurrent breast cancer: steroid hormone receptor analysis of effusion fluid derived cells.

Journal Article Cancer · April 1, 1980 Estrogen and progesterone receptor determination in breast cancer is of significance in determining a patient's potential response to hormonal manipulation. One practical limitation to this procedure has been availability of material for receptor assay. We ... Full text Link to item Cite

Detection of both T-cell and Ia-like antigens on cells from patients with acute myelomonocytic leukemia and chronic myelogenous leukemia in blast crisis.

Journal Article Cancer Res · December 1979 Appropriately absorbed antisera to the lymphoblastoid cell lines HSB and SB detect a human T-lymphocyte-associated antigen (TLAA) and the human Ia-like antigens, respectively. Cells from some patients with acute myelomonocytic leukemia (AMML) and chronic m ... Link to item Cite

Leukopheresis therapy of leukemic reticuloendotheliosis (hairy cell leukemia).

Journal Article Blood · September 1979 Intensive leukopheresis has been valuable in the short-term palliation of chronic lymphocytic and granulocytic leukemias. A 47-yr-old man with refractory leukemic reticuloendotheliosis (hairy cell leukemia) manifested by anemia, thrombocytopenia, elevated ... Link to item Cite

Facilitated light microscopic cytochemical diagnosis of acute myelogenous leukemia.

Journal Article Cancer Res · May 1979 Hydroperoxidase-positive Phi bodies and rods are much more prominent and prevalent than rods visualized with a Romanovsky-type stain (Auer rods) in immature leukocytes of patients with active acute myelogenous leukemia (AML). They are readily observed with ... Link to item Cite

Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary report.

Journal Article Exp Hematol · 1979 Twelve consecutive adult patients with acute myelogenous leukemia have been entered on a treatment protocol which examines the role of "remission-intensification" during maintenance using high-dose chemoradiotherapy and autologous remission marrow transpla ... Link to item Cite

Estrogen receptor determination in percutaneous bone marrow biopsies of patients with metastatic breast cancer.

Journal Article Med Pediatr Oncol · 1979 Estrogen receptor determination in metastatic breast cancer has been shown to be important in determining potential for response to endocrine therapy. One limitation to this procedure can be the availability of neoplastic material for receptor assay. This ... Full text Link to item Cite

The light microscopic demonstration of hydroperoxidase-positive Phi bodies and rods in leukocytes in acute myeloid leukemia.

Journal Article Histochemistry · December 13, 1978 Unique fusiform or spindle-shaped particles (Phi bodies) and rods with hydroperoxidase (catalase and/or peroxidase) activity are present in human granulocyte precursors only in acute myelogenous leukemia (AML). These newly recognized particles are much mor ... Full text Link to item Cite

Chronic lymphocytic leukemia.

Journal Article Cancer · August 1978 Chronic lymphocytic leukemia (CLL) is the commonest type of leukemia seen in Western countries. It affects an older group of individuals than most other varieties of leukemia, and men more often than women, in a ratio of 2:1. The incidence of CLL is signif ... Full text Link to item Cite

I and i antigens on normal and leukemic leukocytes.

Journal Article Cancer · July 1978 Human leukocyte I and i antigens were quantitated using 125I labelled purified antibodies. Binding of these antibodies to leukocytes was dependent on reduced temperature. No significant difference in antigen content was observed between normal and leukemic ... Full text Link to item Cite

Disseminated aspergillosis in a renal transplant patient: Diagnostic difficulties re-emphasized.

Journal Article Johns Hopkins Med J · November 1975 An asymptomatic and radiographically occult lung abscess was the primary focus of infection in this case of fatal disseminated aspergillosis in a renal transplant recipient. Extensive neurological evaluation in response to a change in personality failed to ... Link to item Cite

Population studies of pepsinogen polymorphism.

Journal Article Am J Hum Genet · March 1973 Link to item Cite